Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals

Share:
Related ISIS
Benzinga's Top #PreMarket Gainers
ISIS Pharmaceuticals Cuts License Deal With Bayer AG
Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog (Zacks)

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS) and raised its price target from $12.00 to $17.00.

BMO Capital Markets noted, “We are reiterating our Outperform rating on shares of ISIS and increasing our price target to $17 following our meeting with management. With the near-term focus on the KYNAMRO PDUFA, we are increasingly confident in approval and believe that upside potential extends beyond the initial commercial opportunity and to validation of an emerging late-stage pipeline. Relative to the value of KYNAMRO in HoFH, estimated at an NPV of $3/share, we believe that pipeline value is considerably greater, with an estimated NPV of $14/share, primarily driven by only 1 of 25 programs in the ASO for ApoCIII for triglycerides.”

Isis Pharmaceuticals closed on Friday at $13.28.

Latest Ratings for ISIS

DateFirmActionFromTo
Mar 2015Deutsche BankMaintainsBuy
Mar 2015Stifel NicolausDowngradesBuyHold
Mar 2015Brean CapitalDowngradesBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...